trending Market Intelligence /marketintelligence/en/news-insights/trending/py3khab5-sob6laq5juxva2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Indivior secures license for C4X Discovery's therapies for substance addiction

Blog

Banking Essentials Newsletter - February Edition

Blog

Message in a (Word)Cloud

Six trends shaping the industries and sectors we cover in 2021

Six trends shaping the industries and sectors we cover in 2021


Indivior secures license for C4X Discovery's therapies for substance addiction

Indivior PLC agreed to buy exclusive global rights to develop and commercialize U.K.-based C4X Discovery Holdings PLC's potential treatment for substance addiction.

Under the agreement, the Richmond, Va.-based Indivior would pay C4X $10 million upfront, with potential milestone payments of up to $284 million.

The deal involves C4X Discovery's drugs, including lead candidate C4X3256, that block the orexin-1 protein in the body to decrease addiction related to opioids, alcohol and psychomotor stimulants such as cocaine.